微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 5.04% | 77.43% | 172.31% | 147/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 1.85% | -26.19% | -2.49% | 148/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 1.9% | -29.4% | -19.23% | 145/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 2.35% | -10.28% | -17.27% | 146/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 2.84% | -11.61% | 13.27% | 143/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 2.51% | -3.51% | -6.73% | 147/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 2.69% | -15.03% | 2.65% | 146/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 2.62% | -29.45% | -18.5% | 146/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 3.21% | -22.52% | 23.66% | 142/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 2.6% | -12.28% | -17.86% | 145/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 3.16% | -3.76% | -14.77% | 143/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 3.71% | -9.43% | -10.49% | 143/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 4.15% | -5.23% | 39.99% | 140/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 2.96% | -10.75% | -9.88% | 146/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 3.29% | -7.39% | -19.79% | 138/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 4.1% | 11.95% | -6.34% | 142/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 4.37% | -2.45% | 31.82% | 132/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 3.32% | -11.54% | -6.49% | 145/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 3.55% | -19.62% | -3.03% | 129/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 3.66% | -18.77% | -18.39% | 137/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 4.48% | -27.18% | 19.53% | 119/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 3.75% | -34.05% | -15.02% | 140/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 4.41% | -30.13% | -2.01% | 114/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 4.51% | -39.9% | -26.84% | 125/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 6.16% | -16.44% | 8.25% | 107/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 5.69% | 8.68% | -9.97% | 131/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 6.32% | -1.53% | -15.72% | 103/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 7.5% | -1.5% | 1.73% | 110/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 7.37% | -37.46% | 40.79% | 102/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 5.23% | -20.42% | -18.43% | 128/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 6.42% | 20.63% | -15.69% | 98/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 7.61% | 45.97% | -35.41% | 102/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 11.78% | 92.29% | 79.14% | 95/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 6.58% | -79.68% | 23.65% | 118/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 5.32% | -82.92% | 2.03% | 94/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 5.21% | -83.44% | -14.91% | 100/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 6.13% | -78.29% | -81.07% | 86/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 32.38% | 31.76% | 3.98% | 83/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 31.14% | 6.83% | -1.09% | 60/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 31.48% | 45.29% | 11.5% | 68/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 28.23% | 17.77% | 14.9% | 61/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |